TY - JOUR
T1 - Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase
AU - Suki, Samer
AU - Swan, Forrest
AU - Tucker, Susan
AU - Fritsche, Herbert A.
AU - Redman, John R.
AU - Rodriguez, Maria Alma
AU - Mclaughlin, Peter
AU - Romaguera, Jorge
AU - Hagemeister, Fredrick B.
AU - Velasquez, William S.
AU - Sarris, Andreas H.
AU - Younes, Anas
AU - Cabanillas, Fernando
PY - 1995
Y1 - 1995
N2 - We have previously proposed a staging system for large cell lymphoma using the two serum markers beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH). We recently tested this model in a different cohort of patients with large cell lymphoma and also examined the possible contribution of thymidine kinase (TK), a previously reported serologic prognostic factor. Using an inclusion criteria in the multivariate analysis for both forward and backward selection of p < 0.15, only LDH, B2M, and TK were significant independent prognostic factors for both time to treatment failure (TTF) and survival. Inclusion of TK in the serologic model resulted in three significantly different risk groups for both TTF and survival. Corresponding endpoints at three years were: 1) good risk (no markers elevated, n = 43): 78%, 91%; 2) intermediate risk (1 or 2 markers elevated, n = 47): 41%, 36%; 3) poor risk (3 markers elevated, n = 11): 0%, 0%. This analysis extends the observation of the independent prognostic significance of B2M and LDH. The addition of TK permits a more precise estimate of risk, contributing to the utility of a serological staging system for large cell lymphoma.
AB - We have previously proposed a staging system for large cell lymphoma using the two serum markers beta-2-microglobulin (B2M) and lactate dehydrogenase (LDH). We recently tested this model in a different cohort of patients with large cell lymphoma and also examined the possible contribution of thymidine kinase (TK), a previously reported serologic prognostic factor. Using an inclusion criteria in the multivariate analysis for both forward and backward selection of p < 0.15, only LDH, B2M, and TK were significant independent prognostic factors for both time to treatment failure (TTF) and survival. Inclusion of TK in the serologic model resulted in three significantly different risk groups for both TTF and survival. Corresponding endpoints at three years were: 1) good risk (no markers elevated, n = 43): 78%, 91%; 2) intermediate risk (1 or 2 markers elevated, n = 47): 41%, 36%; 3) poor risk (3 markers elevated, n = 11): 0%, 0%. This analysis extends the observation of the independent prognostic significance of B2M and LDH. The addition of TK permits a more precise estimate of risk, contributing to the utility of a serological staging system for large cell lymphoma.
KW - Beta-2-microglobulin
KW - Lactate dehydrogenase
KW - Large cell lymphoma
KW - Prognostic factors
KW - Thymidine kinase
UR - http://www.scopus.com/inward/record.url?scp=0029127269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029127269&partnerID=8YFLogxK
U2 - 10.3109/10428199509064927
DO - 10.3109/10428199509064927
M3 - Article
C2 - 8580834
AN - SCOPUS:0029127269
SN - 1042-8194
VL - 18
SP - 87
EP - 92
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1-2
ER -